Zhao Jinlu, Mei Jie, Wang Fengxu, Zhao Xinyuan, Ren Yi, Zhao Xingyu, Li Wang, Gao Erli
Department of General Surgery, Τhe Fourth Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Department of Oncology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi 214023, China.
J Oncol. 2022 Aug 31;2022:1469354. doi: 10.1155/2022/1469354. eCollection 2022.
CUB-domain containing protein 1 (CDCP1) is a transmembrane protein acting as an effector of SRC family kinases, which play an oncogenic role in multiple human cancers. However, its clinical and immune correlations in breast cancer (BrCa) have not been explored. To define the expression, prognostic value, and potential molecular role of CDCP1 in BrCa, multiple public datasets, and an in-house cohort were used. Compared with paratumor tissue, CDCP1 was remarkably upregulated in the tumor tissues at both mRNA and protein levels. In the in-house cohort, CDCP1 protein expression was related to several clinicopathological parameters, including age, ER status, PR status, molecular type, and survival status. Kaplan-Meier analysis and Cox regression analysis exhibited that CDCP1 was an important prognostic biomarker in BrCa. In addition, enrichment analysis uncovered that CDCP1 was not only involved in multiple oncogenic pathways, but correlated with overexpression of immune checkpoints. Overall, we reported that increased expression of CDCP1 is a favorable prognostic factor in patients with BrCa. In addition, the correlations between CDCP1 and immune checkpoints provide a novel insight into the adjuvant treatment for immune checkpoint blockade via targeting CDCP1.
含CUB结构域蛋白1（CDCP1）是一种跨膜蛋白，作为SRC家族激酶的效应器，在多种人类癌症中发挥致癌作用。然而，其在乳腺癌（BrCa）中的临床和免疫相关性尚未得到探索。为了确定CDCP1在BrCa中的表达、预后价值和潜在分子作用，使用了多个公共数据集和一个内部队列。与癌旁组织相比，CDCP1在肿瘤组织中的mRNA和蛋白质水平均显著上调。在内部队列中，CDCP1蛋白表达与多个临床病理参数相关，包括年龄、雌激素受体（ER）状态、孕激素受体（PR）状态、分子类型和生存状态。Kaplan-Meier分析和Cox回归分析表明，CDCP1是BrCa的一个重要预后生物标志物。此外，富集分析发现CDCP1不仅参与多种致癌途径，还与免疫检查点的过表达相关。总体而言，我们报告CDCP1表达增加是BrCa患者的一个有利预后因素。此外，CDCP1与免疫检查点之间的相关性为通过靶向CDCP1进行免疫检查点阻断的辅助治疗提供了新的见解。
